

Richard A Scolyer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6697919/richard-a-scolyer-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

719
papers

44,572
citations

102
h-index

190
g-index

833
ext. papers

58,350
ext. citations

7.2
avg, IF

7.17
L-index

#	Paper	IF	Citations
719	Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapy.. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022 ,	4.6	1
718	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).. <i>Annals of Surgical Oncology</i> , 2022 , 1	3.1	1
717	Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus?. <i>British Journal of Dermatology</i> , 2022 ,	4	3
716	Competing risks analysis with missing cause-of-failure-penalized likelihood estimation of cause-specific Cox models.. <i>Statistical Methods in Medical Research</i> , 2022 , 9622802211070254	2.3	
715	Re: Reply to letter to the editor re: 'practical guide on the use of imiquimod cream to treat lentigo maligna'.. <i>Australasian Journal of Dermatology</i> , 2022 ,	1.3	
714	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101701	2.2	2
713	The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment.. <i>Lung Cancer</i> , 2022 , 165, 124-132	5.9	3
712	Reflectance confocal microscopy - a non-invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanoma.. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022 ,	4.6	1
711	Anatomic position determines oncogenic specificity in melanoma.. <i>Nature</i> , 2022 ,	50.4	3
710	Multiple eruptive squamoproliferative lesions during anti-PD1 immunotherapy for metastatic melanoma: pathogenesis, immunohistochemical analysis and treatment.. <i>Dermatologic Therapy</i> , 2022 , e15472	2.2	0
709	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.. <i>Lancet, The</i> , 2022 ,	40	18
708	Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA.. <i>Frontiers in Oncology</i> , 2022 , 12, 820510	5.3	0
707	Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study.. <i>Annals of Surgical Oncology</i> , 2022 , 1	3.1	0
706	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.. <i>Cancer Cell</i> , 2021 ,	24.3	6
705	Case report of a challenging medium-sized congenital melanocytic nevus (CMN): Highlighting a role for reflectance confocal microscopy (RCM) for evaluating changing CMN in children. <i>Pediatric Dermatology</i> , 2021 ,	1.9	
704	Germline variants are associated with increased primary melanoma tumor thickness at diagnosis. <i>Human Molecular Genetics</i> , 2021 , 29, 3578-3587	5.6	1
703	Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2021 ,	5.1	4

702	Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	4
701	High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy. <i>Genes</i> , 2021 , 12,	4.2	1
700	Tumour gene expression signature in primary melanoma predicts long-term outcomes. <i>Nature Communications</i> , 2021 , 12, 1137	17.4	5
699	T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. <i>Cancer Immunology Research</i> , 2021 , 9, 612-623	12.5	3
698	Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. <i>Nature Communications</i> , 2021 , 12, 1434	17.4	5
697	Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. <i>Cancers</i> , 2021 , 13,	6.6	7
696	Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1290-1298	4.6	3
695	Lentiginous melanoma (lentigo maligna and lentigo maligna melanoma) in Australia: clinicopathological characteristics, management and recurrence rates after 10-year follow-up at a tertiary centre. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1315-1322	4.6	4
694	Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. <i>Annals of Oncology</i> , 2021 , 32, 375-383	10.3	4
693	Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e3704-e3713	5.6	19
692	Estimating the potential impact of interventions to reduce over-calling and under-calling of melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1519-1527	4.6	2
691	Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1243-1252	2.2	4
690	A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences. <i>British Journal of Dermatology</i> , 2021 , 185, 101-109	4	4
689	Publication metrics: it really is all about the numbers. <i>Pathology</i> , 2021 , 53, 561-563	1.6	0
688	Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition. <i>Cancers</i> , 2021 , 13,	6.6	5
687	Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9508-9508	2.2	12
686	Predicting sentinel node positivity in patients with melanoma: external validation of a risk-prediction calculator (the Melanoma Institute Australia nomogram) using a large European population-based patient cohort. <i>British Journal of Dermatology</i> , 2021 , 185, 412-418	4	1
685	Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial. <i>Trials</i> , 2021 , 22, 324	2.8	3

684	Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. <i>Genome Medicine</i> , 2021 , 13, 81	14.4	6
683	Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. <i>European Journal of Cancer</i> , 2021 , 148, 51-57	7.5	4
682	Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations. <i>Advances in Therapy</i> , 2021 , 38, 3506-3530	4.1	1
681	Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors. <i>Journal of the Endocrine Society</i> , 2021 , 5, A876-A877	0.4	78
680	The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	7
679	Neoadjuvant Immunotherapy in Melanoma - The New Frontier. <i>Clinical Cancer Research</i> , 2021 , 27, 4133-4135	11.5	1
678	Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2021 , 12, 672521	8.4	1
677	Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. <i>Cancers</i> , 2021 , 13,	6.6	3
676	Counting mitoses: SI(ze) matters!. <i>Modern Pathology</i> , 2021 , 34, 1651-1657	9.8	13
675	Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi. <i>JAMA Dermatology</i> , 2021 , 157, 836-841	5.1	2
674	Mucosal Melanoma: A Review Emphasizing the Molecular Landscape and Implications for Diagnosis and Management. <i>Surgical Pathology Clinics</i> , 2021 , 14, 293-307	3.9	
673	Lentigo maligna: defining margins and predictors of recurrence utilizing clinical, dermoscopic, confocal microscopy and histopathology features. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1811-1820	4.6	0
672	Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis. <i>Pathology</i> , 2021 , 53, 830-835	1.6	1
671	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. <i>Annals of Oncology</i> , 2021 , 32, 766-777	10.3	3
670	Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 1597-1605	6.7	3
669	Histological regression in melanoma: impact on sentinel lymph node status and survival. <i>Modern Pathology</i> , 2021 , 34, 1999-2008	9.8	3
668	Not all melanomas are created equal: a review and call for more research into nodular melanoma. <i>British Journal of Dermatology</i> , 2021 , 185, 700-710	4	2
667	The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence. <i>British Journal of Cancer</i> , 2021 , 124, 156-160	8.7	6

666	Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 1145-1151	3.6	1
665	Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. <i>British Journal of Surgery</i> , 2021 , 108, 550-553	5.3	2
664	Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study. <i>Australasian Journal of Dermatology</i> , 2021 , 62, 168-176	1.3	1
663	GLI activated epithelioid cell tumour: report of a case and proposed new terminology. <i>Pathology</i> , 2021 , 53, 267-270	1.6	4
662	The tumour immune landscape and its implications in cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2021 , 34, 529-549	4.5	8
661	Targeting the Microbiome to Overcome Resistance. <i>Cancer Cell</i> , 2021 , 39, 151-153	24.3	2
660	Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. <i>Pathology</i> , 2021 , 53, 141-156	1.6	25
659	Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape. <i>Experimental Dermatology</i> , 2021 ,	4	4
658	G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma. <i>Clinical Cancer Research</i> , 2021 , 27, 2624-2635	12.9	4
657	Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma. <i>JAMA Dermatology</i> , 2021 , 157, 166-173	5.1	12
656	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021 , 27, 301-309	50.5	65
655	Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. <i>Nature Medicine</i> , 2021 , 27, 256-263	50.5	52
654	Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.. <i>Nature Cancer</i> , 2021 , 2, 693-708	15.4	15
653	ASO Author Reflections: Surgical Resection May Improve the Outcome for Patients with Residual Metastatic Melanoma When Modern Systemic Therapies Have Not Achieved Complete Disease Control. <i>Annals of Surgical Oncology</i> , 2021 , 28, 6124-6125	3.1	
652	Confocal microscopy, dermoscopy, and histopathology features of atypical intraepidermal melanocytic proliferations associated with evolution to melanoma in situ. <i>International Journal of Dermatology</i> , 2021 , 61, 167	1.7	1
651	Characterizing the Clinical Implications of Histologic Regression in Melanoma Requires Clear Diagnostic Criteria That Are Consistently Applied-Reply. <i>JAMA Dermatology</i> , 2021 , 157, 1006-1007	5.1	
650	Cutaneous clear cell sarcoma with an epidermal component mimicking melanoma. <i>Pathology</i> , 2021 ,	1.6	1
649	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. <i>European Journal of Cancer</i> , 2021 , 153, 8-15	7.5	

648	Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. <i>Annals of Surgical Oncology</i> , 2021 , 28, 6109-6123	3.1	2
647	ASO Visual Abstract: Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. <i>Annals of Surgical Oncology</i> , 2021 , 28, 597-598	3.1	1
646	A practical guide on the use of imiquimod cream to treat lentigo maligna. <i>Australasian Journal of Dermatology</i> , 2021 , 62, 478-485	1.3	2
645	LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. <i>Annals of Oncology</i> , 2021 , 32, S1314-S1315	10.3	9
644	Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab 2020 , 8,		6
643	Predicting Sentinel Node Status in Patients With Melanoma: Does Gene Expression Profiling Improve Accuracy?. <i>JCO Precision Oncology</i> , 2020 , 4, 990-991	3.6	2
642	Primary dermal melanoma: clinical behaviour, prognosis and treatment. <i>European Journal of Surgical Oncology</i> , 2020 , 46, 2131-2139	3.6	2
641	Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. <i>Nature Communications</i> , 2020 , 11, 2408	17.4	42
640	Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2719-2727	2.2	29
639	Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors. <i>Frontiers in Oncology</i> , 2020 , 10, 757	5.3	6
638	Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. <i>Frontiers in Immunology</i> , 2020 , 11, 372	8.4	10
637	Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study. <i>BMJ Open</i> , 2020 , 10, e032636	3	3
636	Response to Letter to the Editor: "Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	
635	Temporal and spatial modulation of the tumor and systemic immune response in the murine G1261 glioma model. <i>PLoS ONE</i> , 2020 , 15, e0226444	3.7	11
634	The prognostic significance of microsatellites in cutaneous melanoma. <i>Modern Pathology</i> , 2020 , 33, 1369-1379	13.79	1
633	The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. <i>Archives of Pathology and Laboratory Medicine</i> , 2020 , 144, 500-522	5	95
632	Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. <i>Nature Cancer</i> , 2020 , 1, 197-209	15.4	14
631	Nicotinamide for skin cancer chemoprevention: effects of nicotinamide on melanoma in vitro and in vivo. <i>Photochemical and Photobiological Sciences</i> , 2020 , 19, 171-179	4.2	14

630	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1429-1441	2.2	9
629	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020 , 26, 3671-3681	12.9	27
628	Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2020 , 26, 4064-4071	12.9	20
627	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. <i>Nature Genetics</i> , 2020 , 52, 494-504	36.3	39
626	Abstract 3412: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials 2020 ,		6
625	Abstract 5734: Gut microbiota predicts response and toxicity with neoadjuvant immunotherapy 2020 ,		3
624	Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10015-10015	2.2	13
623	Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS10087-TPS10087	2.2	6
622	Melanoma Prognosis and Staging 2020 , 271-297		1
621	Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management. <i>Australian Journal of General Practice</i> , 2020 , 49, 355-362	1.5	1
620	A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS10088-TPS10088	2.2	1
619	Classification and Histopathology of Melanoma 2020 , 317-379		1
618	From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50 years. <i>Human Pathology</i> , 2020 , 95, 149-160	3.7	3
617	The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 910-919	4.5	7
616	Molecular Profiling of Noncoding Mutations Distinguishes Nevoid Melanomas From Mitotically Active Nevi in Pregnancy. <i>American Journal of Surgical Pathology</i> , 2020 , 44, 357-367	6.7	4
615	Melanoma pathology reporting and staging. <i>Modern Pathology</i> , 2020 , 33, 15-24	9.8	34
614	Estimated risk of progression of lentigo maligna to lentigo maligna melanoma. <i>Melanoma Research</i> , 2020 , 30, 193-197	3.3	13
613	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. <i>Future Oncology</i> , 2020 , 16, 4429-4438	3.6	23

612	Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. <i>Nature Communications</i> , 2020 , 11, 5259	17.4	28
611	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8 T Cells. <i>Immunity</i> , 2020 , 53, 805-823.e15	32.3	22
610	Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2020 , 31, 1569-1579	19.3	8
609	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. <i>Clinical Cancer Research</i> , 2020 , 26, 5926-5933	12.9	21
608	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. <i>Cancer Medicine</i> , 2020 , 9, 8650-8661	4.8	3
607	Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. <i>Cancers</i> , 2020 , 12,	6.6	8
606	Comprehensive analysis of cutaneous and uveal melanoma liver metastases 2020 , 8,		16
605	Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. <i>Cancer</i> , 2020 , 126, 4717-4725	6.4	4
604	Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. <i>JAMA Dermatology</i> , 2020 , 156, 1004-1011	5.1	24
603	Multiplex melanoma families are enriched for polygenic risk. <i>Human Molecular Genetics</i> , 2020 , 29, 2976-2985	5.8	3
602	Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. <i>Clinical and Experimental Immunology</i> , 2020 , 202, 335-352	6.2	3
601	Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Cancers</i> , 2020 , 12,	6.6	9
600	P01.15 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in macroscopic stage III melanoma patients stratified according to interferon-gamma (IFN-gamma) signature [The DONIMI study 2020 , 8, A15.2-A16		1
599	L3 Update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients 2020 , 8, A2.1-A2		2
598	Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. <i>Cancer Immunology Research</i> , 2020 , 8, 1346-1353	12.5	4
597	Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. <i>OncImmunology</i> , 2020 , 9, 1659093	7.2	21
596	Evidence-Based Clinical Practice Guidelines for the Management of Patients with Lentigo Maligna. <i>Dermatology</i> , 2020 , 236, 111-116	4.4	8
595	Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value. <i>Journal of Pathology: Clinical Research</i> , 2020 , 6, 195-206	5.3	17

594	Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. <i>Nature Communications</i> , 2020 , 11, 1897	17.4	63
593	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2020 , 26, 487-504	12.9	138
592	Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life. <i>Annals of Surgical Oncology</i> , 2019 , 26, 4663-4672	3.1	3
591	Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3132-3141	2.2	37
590	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. <i>Lancet Oncology, The</i> , 2019 , 20, 948-960	21.7	186
589	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 961-971	21.7	73
588	LNK suppresses interferon signaling in melanoma. <i>Nature Communications</i> , 2019 , 10, 2230	17.4	8
587	Molecular Genomic Profiling of Melanocytic Nevi. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 1762-1768	17.5	36
586	Pathological re-classification of basal cell carcinomas from the ontrac skin cancer chemoprevention study and the new who skin blue book. <i>Pathology</i> , 2019 , 51, S8	1.6	
585	CD96 Is an Immune Checkpoint That Regulates CD8 T-cell Antitumor Function. <i>Cancer Immunology Research</i> , 2019 , 7, 559-571	12.5	41
584	Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer. <i>Oral Oncology</i> , 2019 , 92, 33-39	4.4	24
583	Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. <i>Annals of Oncology</i> , 2019 , 30, 815-822	10.3	40
582	Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 1314-1322	9.7	17
581	Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis. <i>European Journal of Cancer</i> , 2019 , 110, S21-S22	7.5	
580	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. <i>Cancer Cell</i> , 2019 , 35, 238-255.e6	24.3	230
579	FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019 , 15, 38-47	1.9	8
578	Desmoplastic Melanoma 2019 , 469-481		
577	Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan. <i>Trials</i> , 2019 , 20, 477	2.8	1

576	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. <i>Nature Communications</i> , 2019 , 10, 3163	17.4	113
575	External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. <i>British Journal of Surgery</i> , 2019 , 106, 1319-1326	5.3	4
574	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology, The</i> , 2019 , 20, e378-e389	21.7	88
573	Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 5499-5506	5.6	35
572	Surgical management of the neck in patients with metastatic melanoma in parotid lymph nodes. <i>Journal of Surgical Oncology</i> , 2019 , 120, 1462-1469	2.8	5
571	Abstract 975: Liver metastases (mets) induce systemic immunosuppression and immunotherapy resistance in metastatic melanoma 2019 ,		2
570	Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9500-9500	2.2	3
569	Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9503-9503	2.2	30
568	Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9511-9511	2.2	2
567	Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS9596-TPS9596	2.2	3
566	Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS9605-TPS9605	2.2	14
565	Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. <i>Oncotarget</i> , 2019 , 10, 930-941	3.3	18
564	Management of pigmented skin lesions in childhood and adolescence. <i>Australian Journal of General Practice</i> , 2019 , 48, 539-544	1.5	2
563	Improving diagnostic accuracy for suspicious melanocytic skin lesions: New Australian melanoma clinical practice guidelines stress the importance of clinician/pathologist communication. <i>Australian Journal of General Practice</i> , 2019 , 48, 357-362	1.5	5
562	Classification and Histopathology of Melanoma 2019 , 1-64		
561	Desmoplastic Melanoma 2019 , 1-13		
560	Melanoma Prognosis and Staging 2019 , 1-27		
559	Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS145-TPS145	2.2	

558	Circulating tumor DNA (ctDNA) in metastatic melanoma (MM) patients (pts) with brain metastases (mets).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9581-9581	2.2	0
557	Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9542-9542	2.2	1
556	Management of pigmented skin lesions during pregnancy. <i>Australian Journal of General Practice</i> , 2019 , 48, 621-624	1.5	2
555	Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials. <i>Clinical Cancer Research</i> , 2019 , 25, 3247-3258	12.9	15
554	Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. <i>JAMA Dermatology</i> , 2019 , 155, 502	5.1	
553	18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma. <i>Annals of Oncology</i> , 2019 , 30, v910	10.3	13
552	Novel Immune Targets in Melanoma-Response. <i>Clinical Cancer Research</i> , 2019 , 25, 5424-5425	12.9	1
551	Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. <i>Cancers</i> , 2019 , 11,	6.6	8
550	A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma. <i>Cancers</i> , 2019 , 11,	6.6	7
549	IMMU-04. TEMPORAL AND SPATIAL MODULATION OF THE IMMUNE RESPONSE OF THE MURINE GL261 GLIOMA TUMOUR MICROENVIRONMENT. <i>Neuro-Oncology</i> , 2019 , 21, vi119-vi119	1	78
548	Isolated Immunohistochemistry-positive Cells Without Morphologic Characteristics of Melanoma Should Not Result in Designation as a Positive Sentinel Lymph Node According to the AJCC 8th Edition Staging System. <i>American Journal of Surgical Pathology</i> , 2019 , 43, 1442-1444	6.7	3
547	Hypermethylation of Circulating Free DNA in Cutaneous Melanoma. <i>Applied Sciences (Switzerland)</i> , 2019 , 9, 5074	2.6	1
546	Comment on "Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma". <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, e21-e22	4.5	1
545	Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. <i>International Journal of Cancer</i> , 2019 , 144, 1049-1060	7.5	27
544	bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arrays. <i>Bioinformatics</i> , 2019 , 35, 1350-1357	7.2	1
543	Metastatic Melanoma 2019 , 314-329		
542	RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes. <i>International Journal of Cancer</i> , 2019 , 144, 3070-3085	7.5	43
541	Combined Melanocytic Nevi 2019 , 112-123		

540 Acral and Subungual Melanoma **2019**, 168-180

539 Prognosis, Staging, and Reporting of Melanomas **2019**, 386-396

1

538 Tissue-resident memory CD8 T cells promote melanoma-immune equilibrium in skin. *Nature*, **2019**, 565, 366-371

50.4 149

537 Inter- and inpatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. *Histopathology*, **2019**, 74, 817-828

7.3 13

536 Subungual Melanoma of the Hand. *Annals of Surgical Oncology*, **2019**, 26, 1035-1043

3.1 13

535 A Reduction in Inflammatory Macrophages May Contribute to Skin Cancer Chemoprevention by Nicotinamide. *Journal of Investigative Dermatology*, **2019**, 139, 467-469

4.3 9

534 Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy. *Clinical Cancer Research*, **2019**, 25, 1557-1563

12.9 138

533 Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K -Mutant Melanoma. *Clinical Cancer Research*, **2019**, 25, 1272-1279

12.9 32

532 Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens. *Annals of Surgical Oncology*, **2019**, 26, 25-32

3.1 12

531 Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. *Oncotarget*, **2019**, 8, e1537581

7.2 26

530 The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Population-based data on diagnosis and management. *Australasian Journal of Dermatology*, **2019**, 60, 118-125

1.3 11

529 Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. *Pathology*, **2019**, 51, 39-45

1.6 18

528 Sentinel lymph node biopsy remains the most accurate method of obtaining staging and prognostic information for patients with primary cutaneous melanomas. *Australasian Journal of Dermatology*, **2019**, 60, 75-76

1.3 1

527 The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. *Frontiers in Oncology*, **2018**, 8, 584

5.3 9

526 Pigmented Paget's disease of the nipple mistaken for melanoma in situ: a diagnostic pitfall for the unwary. *Pathology*, **2018**, 50, 364-367

1.6 2

525 An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell*, **2018**, 173, 400-416.e11

56.2 1072

524 Comprehensive Characterization of Cancer Driver Genes and Mutations. *Cell*, **2018**, 173, 371-385.e18

56.2 854

523 Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. *Cell*, **2018**, 173, 291-304.e6

56.2 888

522	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. <i>Cell</i> , 2018 , 173, 386-399.e12	56.2	133
521	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. <i>Cell</i> , 2018 , 173, 305-320.e10	56.2	166
520	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. <i>Cell</i> , 2018 , 173, 338-354.e15	56.2	560
519	Oncogenic Signaling Pathways in The Cancer Genome Atlas. <i>Cell</i> , 2018 , 173, 321-337.e10	56.2	1124
518	Pathogenic Germline Variants in 10,389 Adult Cancers. <i>Cell</i> , 2018 , 173, 355-370.e14	56.2	342
517	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. <i>Cell Reports</i> , 2018 , 23, 282-296.e4	10.6	188
516	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. <i>Cell Reports</i> , 2018 , 23, 227-238.e3	10.6	235
515	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018 , 23, 194-212.e6	10.6	146
514	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. <i>Cell Reports</i> , 2018 , 23, 297-312.e12	10.6	147
513	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018 , 23, 313-326.e5	10.6	295
512	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. <i>Cell Reports</i> , 2018 , 23, 181-193.e7	10.6	366
511	The Immune Landscape of Cancer. <i>Immunity</i> , 2018 , 48, 812-830.e14	32.3	1754
510	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. <i>Cell Reports</i> , 2018 , 23, 172-180.e3	10.6	66
509	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. <i>Cell Reports</i> , 2018 , 23, 213-226.e3	10.6	56
508	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. <i>Cell Reports</i> , 2018 , 23, 239-254.e6	10.6	405
507	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. <i>Cell Reports</i> , 2018 , 23, 255-269.e4	10.6	112
506	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. <i>Cell Reports</i> , 2018 , 23, 270-281.e3	10.6	121
505	Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. <i>European Journal of Cancer</i> , 2018 , 92, 48-53	7.5	15

504	Impact of genomics on the surgical management of melanoma. <i>British Journal of Surgery</i> , 2018 , 105, e315-317	5.47	2
503	Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. <i>JAMA Oncology</i> , 2018 , 4, 717-721	13.4	148
502	Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging. <i>American Journal of Surgical Pathology</i> , 2018 , 42, 359-366	6.7	9
501	RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells. <i>Scientific Reports</i> , 2018 , 8, 653	4.9	8
500	Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8mm Separates Higher-Risk and Lower-Risk Tumors. <i>Annals of Surgical Oncology</i> , 2018 , 25, 894-902	3.1	47
499	High response rate to PD-1 blockade in desmoplastic melanomas. <i>Nature</i> , 2018 , 553, 347-350	50.4	178
498	Telomere sequence content can be used to determine ALT activity in tumours. <i>Nucleic Acids Research</i> , 2018 , 46, 4903-4918	20.1	26
497	CD103 Tumor-Resident CD8 T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment. <i>Clinical Cancer Research</i> , 2018 , 24, 3036-3045	12.9	163
496	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. <i>Cell Systems</i> , 2018 , 6, 271-281.e7	10.6	320
495	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. <i>Cell Systems</i> , 2018 , 6, 282-300.e2	10.6	159
494	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. <i>Cancer Cell</i> , 2018 , 33, 706-720.e9	24.3	275
493	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. <i>Cancer Cell</i> , 2018 , 33, 676-689.e3	24.3	377
492	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. <i>Cancer Cell</i> , 2018 , 33, 721-735.e8	24.3	228
491	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , 2018 , 33, 690-705.e9	24.3	277
490	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. <i>Lancet Oncology</i> , 2018 , 19, 672-681	21.7	512
489	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. <i>Cancer Cell</i> , 2018 , 34, 211-224.e6	24.3	327
488	SIRT6 haploinsufficiency induces BRAF melanoma cell resistance to MAPK inhibitors via IGF signalling. <i>Nature Communications</i> , 2018 , 9, 3440	17.4	51
487	Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis. <i>British Journal of Cancer</i> , 2018 , 119, 713-723	8.7	2

486	History of Melanoma 2018 , 1-13		1
485	Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling. <i>Clinical Cancer Research</i> , 2018 , 24, 4494-4504	12.9	14
484	Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: A phase II randomised study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D+T) in BRAF V600 mutant resectable stage IIIb/c/d melanoma (NeoTrio trial).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS9604-TPS9604	2.2	8
483	Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS9606-TPS9606	2.2	7
482	Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9518-9518	2.2	
481	Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features. <i>Scientific Data</i> , 2018 , 5, 180245	8.2	12
480	A 14-Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma. <i>Proteomics - Clinical Applications</i> , 2018 , 12, e1700094	3.1	
479	The Importance of Population-Based Estimates of Melanocytic Pathology. <i>JAMA Dermatology</i> , 2018 , 154, 15-17	5.1	1
478	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018 , 24, 1260-1270	12.9	164
477	Trajectories of premalignancy during the journey from melanocyte to melanoma. <i>Pathology</i> , 2018 , 50, 16-23	1.6	17
476	Punch 'scoring': a technique that facilitates melanoma diagnosis of clinically suspicious pigmented lesions. <i>Histopathology</i> , 2018 , 72, 294-304	7.3	5
475	OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO). <i>Annals of Oncology</i> , 2018 , 29, viii734	10.3	5
474	ASO Author Reflections: Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas. <i>Annals of Surgical Oncology</i> , 2018 , 25, 918-919	3.1	0
473	Epigenetic profiling for the molecular classification of metastatic brain tumors. <i>Nature Communications</i> , 2018 , 9, 4627	17.4	58
472	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. <i>Cell Systems</i> , 2018 , 7, 422-437.e7	10.6	85
471	Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. <i>Cell Reports</i> , 2018 , 25, 1304-1317.e5	10.6	152
470	Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma. <i>Pathology</i> , 2018 , 50, 648-653	1.6	4
469	Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts. <i>Journal of Surgical Oncology</i> , 2018 , 118, 599-605	2.8	8

468	Staging of Cutaneous Melanoma: Is There Room for Further Improvement?. <i>JAMA Network Open</i> , 2018 , 1, e180086	10.4	2
467	Melanoma protective antitumor immunity activated by catalytic DNA. <i>Oncogene</i> , 2018 , 37, 5115-5126	9.2	11
466	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2018 , 29, 1861-1868	10.3	77
465	Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2017 , 24, 1378-1385	3.1	16
464	SF3B1 and BAP1 mutations in blue nevus-like melanoma. <i>Modern Pathology</i> , 2017 , 30, 928-939	9.8	57
463	Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas. <i>Laboratory Investigation</i> , 2017 , 97, 130-145	5.9	25
462	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. <i>Clinical Cancer Research</i> , 2017 , 23, 5024-5033	12.9	141
461	Whole-genome landscapes of major melanoma subtypes. <i>Nature</i> , 2017 , 545, 175-180	50.4	662
460	The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1. <i>Clinical Cancer Research</i> , 2017 , 23, 2921-2923	12.9	4
459	Authors' response to a reply to 'A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients'. <i>British Journal of Dermatology</i> , 2017 , 176, 552-553	4	1
458	Resistance to PD1/PDL1 checkpoint inhibition. <i>Cancer Treatment Reviews</i> , 2017 , 52, 71-81	14.4	305
457	Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 2033-2035	4.3	20
456	Computer-assisted diagnosis for skin cancer: have we been outsmarted?. <i>Lancet, The</i> , 2017 , 389, 1962-1964	4.4	9
455	Detection of desmoplastic melanoma with dermoscopy and reflectance confocal microscopy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 2016-2024	4.6	17
454	Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. <i>Annals of Oncology</i> , 2017 , 28, 1130-1136	10.3	186
453	Primary Melanoma of the Lung 2017 , 285-292		2
452	5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms. <i>Journal of Cutaneous Pathology</i> , 2017 , 44, 249-255	1.7	10
451	Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi. <i>Modern Pathology</i> , 2017 , 30, 350-356	9.8	44

450	Mutation load in melanoma is affected by MC1R genotype. <i>Pigment Cell and Melanoma Research</i> , 2017 , 30, 255-258	4.5	15
449	Skp2-Mediated Stabilization of MTH1 Promotes Survival of Melanoma Cells upon Oxidative Stress. <i>Cancer Research</i> , 2017 , 77, 6226-6239	10.1	31
448	Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017 , 67, 472-492	220.7	1044
447	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. <i>Immunity</i> , 2017 , 47, 789-802.e9	32.3	142
446	Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. <i>Biomarker Research</i> , 2017 , 5, 32	8	16
445	Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1721-1729	2.2	32
444	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. <i>Nature Communications</i> , 2017 , 8, 607	17.4	80
443	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2017 , 23, 6054-6061	12.9	48
442	Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center. <i>Modern Pathology</i> , 2017 , 30, 1538-1550 ²²	8.8	22
441	Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas. <i>European Journal of Cancer</i> , 2017 , 82, 167-170	7.5	8
440	Germline BAP1 mutations also predispose to cutaneous squamous cell carcinoma. <i>Pathology</i> , 2017 , 49, 539-542	1.6	9
439	Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. <i>Modern Pathology</i> , 2017 , 30, 1666-1676	9.8	98
438	Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (. <i>Annals of Surgical Oncology</i> , 2017 , 24, 660	3.1	1
437	Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1421-1433	8.9	97
436	MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. <i>Cancer Research</i> , 2017 , 77, 4697-4709	10.1	87
435	Poor Adherence to National Clinical Management Guidelines: A Population-Based, Cross-Sectional Study of the Surgical Management of Melanoma in New South Wales, Australia. <i>Annals of Surgical Oncology</i> , 2017 , 24, 2080-2088	3.1	15
434	Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. <i>Cancer Research</i> , 2017 , 77, 4684-4696	10.1	67
433	Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered transcript splicing. <i>Biomarker Research</i> , 2017 , 5, 17	8	6

432	Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells. <i>Laboratory Investigation</i> , 2017 , 97, 176-186	5.9	12
431	In vivo reflectance confocal microscopy for evaluating melanoma of the lip and its differential diagnoses. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017 , 123, 84-94	2	9
430	Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions. <i>British Journal of Dermatology</i> , 2017 , 177, 574-577	4	4
429	Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma. <i>Annals of Oncology</i> , 2017 , 28, v432	10.3	28
428	Programmed Death-Ligand 1 Expression in a Large Cohort of Pediatric Patients With Solid Tumor and Association With Clinicopathologic Features in Neuroblastoma.. <i>JCO Precision Oncology</i> , 2017 , 1, 1-12	3.6	5
427	A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9508-9508	2.2	82
426	Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9541-9541	2.2	2
425	Preliminary results from the international neoadjuvant melanoma consortium (INMC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9581-9581	2.2	10
424	Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS9600-TPS9600	2.2	4
423	A multi-step classifier addressing cohort heterogeneity improves performance of prognostic biomarkers in three cancer types. <i>Oncotarget</i> , 2017 , 8, 2807-2815	3.3	2
422	Melanoma of the Skin 2017 , 563-586		58
421	Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 51-51	2.2	
420	Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9558-9558	2.2	
419	In Vivo Reflectance Confocal Microscopy for the Diagnosis of Melanoma and Melanotic Macules of the Lip. <i>JAMA Dermatology</i> , 2017 , 153, 882-891	5.1	19
418	Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 245-254	4.3	54
417	Imaging mass spectrometry assists in the classification of diagnostically challenging atypical Spitzoid neoplasms. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 1176-1186.e4	4.5	36
416	Atypical Ewing sarcoma breakpoint region 1 fluorescence in-situ hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases. <i>Histopathology</i> , 2016 , 69, 1000-1017	7.3	11
415	Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. <i>Oncolimmunology</i> , 2016 , 5, e1238557	7.2	89

414	Lethal melanoma in children: a clinicopathological study of 12 cases. <i>Pathology</i> , 2016 , 48, 705-711	1.6	7
413	Angiomatoid Spitz naevus: novel observations and clues to diagnosis of a rare variant. <i>Pathology</i> , 2016 , 48, 739-742	1.6	1
412	BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. <i>Histopathology</i> , 2016 , 69, 680-6	7.3	23
411	Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. <i>Histopathology</i> , 2016 , 69, 25-34	7.3	138
410	Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1-2mm in Thickness): Analysis of 2131 Patients Treated at a Single Center. <i>Annals of Surgical Oncology</i> , 2016 , 23, 1071-81	3.1	25
409	The regenerating naevus. <i>Pathology</i> , 2016 , 48, 108-12	1.6	6
408	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. <i>Clinical Cancer Research</i> , 2016 , 22, 3915-23	12.9	73
407	Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. <i>Pathology</i> , 2016 , 48, 261-6	1.6	28
406	Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. <i>Modern Pathology</i> , 2016 , 29, 347-58	9.8	28
405	Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. <i>Pathology</i> , 2016 , 48, 194-202	1.6	13
404	The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Case-Control Study. <i>Annals of Surgical Oncology</i> , 2016 , 23, 1082-9	3.1	30
403	Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system. <i>Journal of Neuro-Oncology</i> , 2016 , 127, 435-44	4.8	41
402	Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of Stage III patients. <i>Modern Pathology</i> , 2016 , 29, 122-30	9.8	22
401	Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9583-9583	2.2	7
400	A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: The Anti-PD1 Brain Collaboration (ABC Study).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS9591-TPS9591	2.2	5
399	PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials. <i>Oncotarget</i> , 2016 , 7, 77010-77020	3.3	35
398	Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation. <i>Pigment Cell and Melanoma Research</i> , 2016 , 29, 444-52	4.5	2
397	Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation. <i>American Journal of Surgical Pathology</i> , 2016 , 40, 786-95	6.7	31

396	A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. <i>British Journal of Dermatology</i> , 2016 , 175, 1073-1075	4	62
395	Dermoscopy and in vivo confocal microscopy are complementary techniques for diagnosis of difficult amelanotic and light-coloured skin lesions. <i>British Journal of Dermatology</i> , 2016 , 175, 1311-1319 ⁴		47
394	Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma: a prospective, consecutive, cohort study of 168 cases. <i>British Journal of Dermatology</i> , 2016 , 175, 1290-1300 ⁴		37
393	The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. <i>Science Translational Medicine</i> , 2016 , 8, 369ra177	17.5	14
392	Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?. <i>European Journal of Cancer</i> , 2016 , 62, 76-85	7.5	145
391	The molecular profile of metastatic melanoma in Australia. <i>Pathology</i> , 2016 , 48, 188-93	1.6	18
390	Critical Assessment of Clinical Prognostic Tools in Melanoma. <i>Annals of Surgical Oncology</i> , 2016 , 23, 2753-61	3.61	36
389	Breslow Thickness Measurements of Melanomas Around American Joint Committee on Cancer Staging Cut-Off Points: Imprecision and Terminal Digit Bias Have Important Implications for Staging and Patient Management. <i>Annals of Surgical Oncology</i> , 2016 , 23, 2658-63	3.1	15
388	Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. <i>Pathology</i> , 2016 , 48, 574-80	1.6	48
387	SOX10 expression in cutaneous scars: a potential diagnostic pitfall in the evaluation of melanoma re-excision specimens. <i>Pathology</i> , 2016 , 48, 626-8	1.6	7
386	Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information. <i>International Journal of Cancer</i> , 2015 , 136, 863-74	7.5	48
385	Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases. <i>Annals of Surgical Oncology</i> , 2015 , 22, 1959-66	3.1	58
384	Role of frozen section analysis in nodular thyroid pathology. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2015 , 132, 67-70	2.2	15
383	Sex differences in melanoma survival are not related to mitotic rate of the primary tumor. <i>Annals of Surgical Oncology</i> , 2015 , 22, 1598-603	3.1	14
382	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015 , 161, 1681-96	56.2	1807
381	Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. <i>Lancet Oncology, The</i> , 2015 , 16, 1049-1060	21.7	125
380	The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. <i>EBioMedicine</i> , 2015 , 2, 671-80	8.8	67
379	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. <i>Clinical Cancer Research</i> , 2015 , 21, 3140-8	12.9	97

378	Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. <i>Modern Pathology</i> , 2015 , 28, 884-94	9.8	23
377	In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. <i>Annals of Surgical Oncology</i> , 2015 , 22, 475-81	3.1	99
376	Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma. <i>Molecular Cancer Research</i> , 2015 , 13, 670-80	6.6	21
375	PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. <i>Pigment Cell and Melanoma Research</i> , 2015 , 28, 245-53	4.5	291
374	New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, e52-6	2.2	25
373	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. <i>Modern Pathology</i> , 2015 , 28, 1535-44	9.8	58
372	Recurrent inactivating RASA2 mutations in melanoma. <i>Nature Genetics</i> , 2015 , 47, 1408-10	36.3	73
371	A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. <i>New England Journal of Medicine</i> , 2015 , 373, 1618-26	59.2	318
370	Eruptive disseminated Spitz naevus (EDSN) in a young girl of Indian origin. <i>Australasian Journal of Dermatology</i> , 2015 , 56, 134-6	1.3	4
369	Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. <i>Nature Genetics</i> , 2015 , 47, 1194-9	36.3	177
368	Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 10995-1000	11.5	112
367	Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. <i>Cancer Microenvironment</i> , 2015 , 8, 111-8	6.1	13
366	MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis. <i>Pigment Cell and Melanoma Research</i> , 2015 , 28, 254-66	4.5	47
365	Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 532-541	4.3	59
364	3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate. <i>European Journal of Cancer</i> , 2015 , 51, S666	7.5	6
363	Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. <i>Pathology</i> , 2015 , 47, 683-93	1.6	6
362	A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. <i>Clinical Genetics</i> , 2015 , 88, 267-72	4	73
361	Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. <i>Pigment Cell and Melanoma Research</i> , 2015 , 28, 607-10	4.5	47

360	BAP1-inactivated spitzoid naevi. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 722	6.7	12
359	Punch biopsy of melanoma causing tumour cell implantation: another peril of utilising partial biopsies for melanocytic tumours. <i>Australasian Journal of Dermatology</i> , 2015 , 56, 227-31	1.3	0
358	Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. <i>Cancer</i> , 2015 , 121, 3826-35	6.4	33
357	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. <i>Oncotarget</i> , 2015 , 6, 42008-18	3.3	238
356	Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma. <i>Melanoma Research</i> , 2015 , 25, 91-4	3.3	18
355	First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. <i>BMC Research Notes</i> , 2015 , 8, 192	2.3	15
354	Detailed pathological examination of completion node dissection specimens and outcome in melanoma patients with minimal (. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2972-7	3.1	11
353	Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 809-15.e1	4.5	33
352	RIP1 Kinase Is an Oncogenic Driver in Melanoma. <i>Cancer Research</i> , 2015 , 75, 1736-48	10.1	49
351	Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. <i>Clinical Cancer Research</i> , 2015 , 21, 98-105	12.9	49
350	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. <i>Lung Cancer</i> , 2015 , 89, 181-8	5.9	195
349	BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1680-92	6.1	22
348	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , 2015 , 75, 5228-34	10.1	196
347	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , 2015 , 51, 2792-9	7.5	202
346	Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9011-9011	2.2	7
345	Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS9091-TPS9091	2.2	4
344	INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. <i>Oncotarget</i> , 2015 , 6, 39891-907	3.3	32
343	Whole exome paraffin sequencing (WEPS) of same-patient (pt) primary, extracranial, and melanoma brain metastases (PEB) to identify new driver and clonal evolution genetic events.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20033-e20033	2.2	

342	PD-L1 expression, immune cell correlates, and PD-1+ lymphocytes in sentinel lymph node positive melanoma patients: Implications for adjuvant PD-1 clinical trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20011-e20011	2.2	
341	BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9008-9008	2.2	2
340	BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. <i>Clinical Cancer Research</i> , 2014 , 20, 1965-77	12.9	340
339	Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. <i>Methods in Molecular Biology</i> , 2014 , 1102, 287-324	1.4	61
338	Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. <i>Journal of Immunology</i> , 2014 , 192, 2505-13	5.3	57
337	Diffuse melanosis cutis in the setting of BRAF(V600E) metastatic melanoma. <i>International Journal of Dermatology</i> , 2014 , 53, 1409-11	1.7	3
336	Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. <i>Oncogene</i> , 2014 , 33, 1158-66	9.2	48
335	Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. <i>Cancer Discovery</i> , 2014 , 4, 423-33	24.4	180
334	Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 816-23	2.2	17
333	Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors. <i>Modern Pathology</i> , 2014 , 27, 936-44	9.8	40
332	Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. <i>British Journal of Cancer</i> , 2014 , 111, 292-9	8.7	72
331	Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease. <i>Annals of Surgical Oncology</i> , 2014 , 21, 3108-16	3.1	29
330	Pathology review significantly affects diagnosis and treatment of melanoma patients: an analysis of 5011 patients treated at a melanoma treatment center. <i>Annals of Surgical Oncology</i> , 2014 , 21, 2245-51	3.1	27
329	Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. <i>Human Molecular Genetics</i> , 2014 , 23, 226-38	5.6	82
328	Primary oesophageal melanoma - a case report. <i>World Journal of Surgical Oncology</i> , 2014 , 12, 77	3.4	3
327	DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. <i>Neuro-Oncology</i> , 2014 , 16, 1499-509	1	39
326	The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. <i>European Journal of Cancer</i> , 2014 , 50, 111-20	7.5	102
325	The optimum excision margin and regional node management for primary cutaneous T3 melanomas (2-4 mm in Thickness): a retrospective study of 1587 patients treated at a single center. <i>Annals of Surgery</i> , 2014 , 260, 1095-102	7.8	9

324	Outcome following sentinel node biopsy plus wide local excision versus wide local excision only for primary cutaneous melanoma: analysis of 5840 patients treated at a single institution. <i>Annals of Surgery</i> , 2014 , 260, 149-57	7.8	33
323	How anti-PD1 treatments are changing the management of melanoma. <i>Melanoma Management</i> , 2014 , 1, 165-172	2.1	3
322	Reply to M. Perier-Muzet et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3203	2.2	2
321	Genetic and clinico-pathologic analysis of metastatic uveal melanoma. <i>Modern Pathology</i> , 2014 , 27, 175-83	9.3	66
320	A novel hypoxia-associated subset of FN1 high MITF low melanoma cells: identification, characterization, and prognostic value. <i>Modern Pathology</i> , 2014 , 27, 1088-100	9.8	14
319	Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. <i>Modern Pathology</i> , 2014 , 27, 1193-202	9.8	14
318	Oncogenic suppression of PHLPP1 in human melanoma. <i>Oncogene</i> , 2014 , 33, 4756-66	9.2	22
317	Intra-patient heterogeneity of BRAF mutation status: fact or fiction?. <i>British Journal of Cancer</i> , 2014 , 111, 1678-9	8.7	7
316	Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. <i>Nature Communications</i> , 2014 , 5, 5694	17.4	223
315	Pharmacologically antagonizing the CXCR4-CXCL12 chemokine pathway with AMD3100 inhibits sunlight-induced skin cancer. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 1091-1100	4.3	44
314	Atypical naevus spilus: detection by in vivo confocal microscopy. <i>Clinical and Experimental Dermatology</i> , 2014 , 39, 616-9	1.8	2
313	Surveillance for treatment failure of lentigo maligna with dermoscopy and in vivo confocal microscopy: new descriptors. <i>British Journal of Dermatology</i> , 2014 , 170, 1305-12	4	49
312	Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1 α and oxidative phosphorylation in melanoma. <i>Cancer Research</i> , 2014 , 74, 7037-47	10.1	126
311	Intrapatient homogeneity of BRAFV600E expression in melanoma. <i>American Journal of Surgical Pathology</i> , 2014 , 38, 377-82	6.7	56
310	Atypical Spitzoid neoplasms: a review of potential markers of biological behavior including sentinel node biopsy. <i>Melanoma Research</i> , 2014 , 24, 437-47	3.3	24
309	Histomorphologic assessment and interobserver diagnostic reproducibility of atypical spitzoid melanocytic neoplasms with long-term follow-up. <i>American Journal of Surgical Pathology</i> , 2014 , 38, 934-40	6.7	110
308	Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. <i>Pathology</i> , 2014 , 46, 193-8	1.6	14
307	A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. <i>Cancer Discovery</i> , 2014 , 4, 69-79	24.4	118

306	Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. <i>Pigment Cell and Melanoma Research</i> , 2014 , 27, 1106-16	4.5	13
305	Radiotherapy for lentigo maligna: a literature review and recommendations for treatment. <i>British Journal of Dermatology</i> , 2014 , 170, 52-8	4	59
304	Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients. <i>Clinical and Experimental Metastasis</i> , 2014 , 31, 407-21	4.7	6
303	Genetic alterations and personalized medicine in melanoma: progress and future prospects. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt435	9.7	57
302	Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/ β -catenin signaling. <i>PLoS ONE</i> , 2014 , 9, e94748	3.7	28
301	A highly recurrent RPS27 5'UTR mutation in melanoma. <i>Oncotarget</i> , 2014 , 5, 2912-7	3.3	45
300	TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. <i>Oncotarget</i> , 2014 , 5, 10127-39	3.3	28
299	Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells. <i>Oncotarget</i> , 2014 , 5, 11237-51	3.3	29
298	Correlation between pre-existing MEK1P124 mutations and clinical and in vitro response to BRAF inhibitors in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9004-9004	2.2	
297	Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation-positive melanoma with metastases to the brain (BRV116521).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS9112-TPS9112	2.2	
296	Metastatic Melanoma 2014 , 529-567		
295	Reflectance confocal microscopy for diagnosis of mammary and extramammary Paget's disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, e24-9	4.6	31
294	Improving management and patient care in lentigo maligna by mapping with in vivo confocal microscopy. <i>JAMA Dermatology</i> , 2013 , 149, 692-8	5.1	95
293	Reproducibility of AJCC staging parameters in primary cutaneous melanoma: an analysis of 4,924 cases. <i>Annals of Surgical Oncology</i> , 2013 , 20, 3969-75	3.1	19
292	Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. <i>Pigment Cell and Melanoma Research</i> , 2013 , 26, 499-508	4.5	31
291	Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. <i>Pigment Cell and Melanoma Research</i> , 2013 , 26, 852-60	4.5	40
290	The important role of radiation treatment in the management of Merkel cell carcinoma. <i>British Journal of Dermatology</i> , 2013 , 169, 975-82	4	22
289	Completion lymph node dissection in melanoma patients with positive sentinel lymph nodes. <i>European Journal of Surgical Oncology</i> , 2013 , 39, 1164-5	3.6	1

288	Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients. <i>European Journal of Surgical Oncology</i> , 2013 , 39, 179-84	3.6	19
287	Mitotic rate in melanoma should be recorded as the number of mitoses per mm ² (not per high power field): surgeons tell your pathologists!. <i>American Journal of Surgery</i> , 2013 , 206, 142-3	2.7	5
286	Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). <i>Lancet, The</i> , 2013 , 381, 1835-43	4.0	69
285	Margins of excision and prognostic factors for cutaneous eyelid melanomas. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2013 , 66, 1066-73	1.7	32
284	BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. <i>British Journal of Cancer</i> , 2013 , 108, 924-31	8.7	50
283	Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 1269-74	4.3	37
282	Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR). <i>American Journal of Surgical Pathology</i> , 2013 , 37, 1797-814	6.7	86
281	Outcomes of atypical spitz tumors with chromosomal copy number aberrations and conventional melanomas in children. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 1387-94	6.7	78
280	BAP1 expression in cutaneous melanoma: a pilot study. <i>Pathology</i> , 2013 , 45, 606-9	1.6	28
279	Tumours associated with BAP1 mutations. <i>Pathology</i> , 2013 , 45, 116-26	1.6	192
278	Digital papillary adenocarcinoma: a tumour that should be considered in the differential diagnosis of neoplasms involving the digits. <i>Pathology</i> , 2013 , 45, 55-61	1.6	13
277	Dermoscopic evaluation of nodular melanoma. <i>JAMA Dermatology</i> , 2013 , 149, 699-709	5.1	79
276	Prominent angiotropism in a small atypical spitzoid dysplastic melanocytic naevus: what is its significance?. <i>Pathology</i> , 2013 , 45, 701-3	1.6	2
275	Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. <i>Oncolmmunology</i> , 2013 , 2, e25564	7.2	6
274	Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes. <i>Pigment Cell and Melanoma Research</i> , 2013 , 26, 326-37	4.5	29
273	Asymptomatic linear pigmentation of the skin. Linear lichen planus pigmentus (LPP). <i>International Journal of Dermatology</i> , 2013 , 52, 935-7	1.7	0
272	Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden. <i>Pigment Cell and Melanoma Research</i> , 2013 , 26, 708-22	4.5	10
271	Liver resection for metastatic melanoma: equivalent survival for cutaneous and ocular primaries. <i>Journal of Surgical Oncology</i> , 2013 , 108, 129-35	2.8	35

270	p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes. <i>Pigment Cell and Melanoma Research</i> , 2013 , 26, 236-46	4.5	16
269	BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. <i>Clinical Cancer Research</i> , 2013 , 19, 4589-98	12.9	102
268	PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. <i>Nature Communications</i> , 2013 , 4, 1508	17.4	61
267	AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. <i>Cell Death and Disease</i> , 2013 , 4, e914	9.8	47
266	Recent insights into the molecular pathogenesis of mammary phyllodes tumours. <i>Journal of Clinical Pathology</i> , 2013 , 66, 496-505	3.9	24
265	Controversies and evolving concepts in the diagnosis, classification and management of lentigo maligna. <i>Expert Review of Dermatology</i> , 2013 , 8, 195-214		6
264	BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 509-17	4.3	131
263	Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 61-5	6.7	254
262	Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 676-84	6.7	141
261	The importance of adequate primary tumor excision margins and sentinel node biopsy in achieving optimal locoregional control for patients with thick primary melanomas. <i>Annals of Surgery</i> , 2013 , 258, 152-7	7.8	45
260	Adjuvant radiotherapy after lymphadenectomy in melanoma patients: Final results of an intergroup randomized trial (ANZMTG 0.1.02/TROG 02.01).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9001-9001	2.2	4
259	Involvement of β -catenin and E-cadherin in the development of mammary phyllodes tumours. <i>Histopathology</i> , 2012 , 61, 667-74	7.3	15
258	Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma. <i>Histopathology</i> , 2012 , 61, 889-98	7.3	33
257	Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. <i>Histopathology</i> , 2012 , 61, 702-10	7.3	29
256	The absence of Brm exacerbates photocarcinogenesis. <i>Experimental Dermatology</i> , 2012 , 21, 599-604	4	18
255	Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma. <i>British Journal of Dermatology</i> , 2012 , 166, 1319-26	4	7
254	Surgical management of melanoma lung metastasis: an analysis of survival outcomes in 292 consecutive patients. <i>Annals of Surgical Oncology</i> , 2012 , 19, 1774-81	3.1	32
253	Sentinel lymph nodes containing very small (. <i>Annals of Surgical Oncology</i> , 2012 , 19, 1089-99	3.1	36

252	Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma. <i>Annals of Surgical Oncology</i> , 2012 , 19, 1782-9	3.1	25
251	Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene. <i>Genes Chromosomes and Cancer</i> , 2012 , 51, 452-61	5	22
250	Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. <i>Lancet Oncology</i> , 2012 , 13, 589-97	21.7	188
249	Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. <i>Cell</i> , 2012 , 150, 1135-46	56.2	595
248	Increasing tumor thickness is associated with recurrence and poorer survival in patients with Merkel cell carcinoma. <i>Annals of Surgical Oncology</i> , 2012 , 19, 3325-34	3.1	40
247	Human 8-oxoguanine-DNA glycosylase-1 is downregulated in human basal cell carcinoma. <i>Molecular Genetics and Metabolism</i> , 2012 , 106, 127-30	3.7	18
246	In vivo confocal microscopy for diagnosis of melanoma and basal cell carcinoma using a two-step method: analysis of 710 consecutive clinically equivocal cases. <i>Journal of Investigative Dermatology</i> , 2012 , 132, 2386-2394	4.3	213
245	Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2012 , 167, 1153-60	4	138
244	Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas. <i>Annals of Surgical Oncology</i> , 2012 , 19, 1024-33	3.1	42
243	Absence of distinguishing senescence traits in human melanocytic nevi. <i>Journal of Investigative Dermatology</i> , 2012 , 132, 2226-34	4.3	37
242	E-cadherin expression in the epithelial components of mammary phyllodes tumors. <i>Human Pathology</i> , 2012 , 43, 2117-23	3.7	14
241	The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro. <i>Journal of Pathology</i> , 2012 , 226, 451-62	9.4	32
240	Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. <i>Nature Communications</i> , 2012 , 3, 724	17.4	500
239	A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 888-97	6.1	44
238	Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. <i>Cancer</i> , 2012 , 118, 4519-29	6.4	24
237	Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2678-83	2.2	472
236	Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. <i>Clinical Cancer Research</i> , 2012 , 18, 1386-94	12.9	494
235	SOX2 contributes to melanoma cell invasion. <i>Laboratory Investigation</i> , 2012 , 92, 362-70	5.9	72

234	Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. <i>Oncol Immunology</i> , 2012 , 1, 997-999	7.2	24
233	Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. <i>Modern Pathology</i> , 2012 , 25, 828-37	9.8	41
232	Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2704-8	6.1	68
231	Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. <i>Clinical Cancer Research</i> , 2012 , 18, 3242-9	12.9	344
230	Review and cross-validation of gene expression signatures and melanoma prognosis. <i>Journal of Investigative Dermatology</i> , 2012 , 132, 274-83	4.3	48
229	Peritoneal melanosis associated with metastatic melanoma involving the omentum. <i>Pathology</i> , 2012 , 44, 255-7	1.6	12
228	Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanoma. <i>Annals of Surgery</i> , 2012 , 255, 1165-70	7.8	43
227	Endocrine mucin producing sweat gland carcinoma: a clinicopathological analysis of three cases. <i>Pathology</i> , 2012 , 44, 568-71	1.6	12
226	Cellular blue naevus involving the urinary bladder. <i>Pathology</i> , 2012 , 44, 664-8	1.6	2
225	Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. <i>Annals of Surgery</i> , 2012 , 255, 128-33	7.8	83
224	Primary Melanoma of the Lung 2012 , 335-341		
223	Melanoma - a management guide for GPs. <i>Australian Family Physician</i> , 2012 , 41, 470-3		6
222	Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. <i>Molecular Oncology</i> , 2011 , 5, 124-36	7.9	103
221	Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. <i>European Journal of Cancer</i> , 2011 , 47, 460-9	7.5	44
220	BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. <i>Pigment Cell and Melanoma Research</i> , 2011 , 24, 345-51	4.5	151
219	The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. <i>Pathology</i> , 2011 , 43, 657-71	1.6	34
218	Follicular dendritic cell sarcoma of the lung: a report of two cases highlighting its pathological features and diagnostic pitfalls. <i>Pathology</i> , 2011 , 43, 67-70	1.6	4
217	Factors predicting recurrence and survival in sentinel lymph node-positive melanoma patients. <i>Annals of Surgery</i> , 2011 , 253, 1155-64	7.8	30

216	BRM and BRG1 subunits of the SWI/SNF chromatin remodelling complex are downregulated upon progression of benign skin lesions into invasive tumours. <i>British Journal of Dermatology</i> , 2011 , 164, 1221-47	25
215	Clinical and pathological features of metastases of primary cutaneous desmoplastic melanoma. <i>Histopathology</i> , 2011 , 58, 886-95	7.3 16
214	Treatment and prognostic significance of positive interval sentinel nodes in patients with primary cutaneous melanoma. <i>Annals of Surgical Oncology</i> , 2011 , 18, 3292-9	3.1 22
213	The diagnostic value of adding dynamic scintigraphy to standard delayed planar imaging for sentinel node identification in melanoma patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011 , 38, 1999-2004	8.8 12
212	Melanoma pathology: important issues for clinicians involved in the multidisciplinary care of melanoma patients. <i>Surgical Oncology Clinics of North America</i> , 2011 , 20, 19-37	2.7 16
211	Selective loss of wild-type p16(INK4a) expression in human nevi. <i>Journal of Investigative Dermatology</i> , 2011 , 131, 2329-32	4.3 8
210	Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1239-46	2.2 802
209	Reply to I. Satzger et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, e316-e317	2.2
208	MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 15840-5	11.5 150
207	Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma. <i>Journal of Investigative Dermatology</i> , 2011 , 131, 1631-8	4.3 122
206	Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi).. <i>Journal of Clinical Oncology</i> , 2011 , 29, 8542-8542	2.2 6
205	Nevus/Melanocytoma/Melanoma: an emerging paradigm for classification of melanocytic neoplasms?. <i>Archives of Pathology and Laboratory Medicine</i> , 2011 , 135, 300-6	5 49
204	Melanoma exhibiting cartilaginous differentiation. <i>Histopathology</i> , 2010 , 56, 815-21	7.3 10
203	Quality of histopathological reporting on melanoma and influence of use of a synoptic template. <i>Histopathology</i> , 2010 , 56, 768-74	7.3 34
202	p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours. <i>Histopathology</i> , 2010 , 56, 868-75	7.3 26
201	The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented and nonpigmented macules of the face. <i>Journal of Investigative Dermatology</i> , 2010 , 130, 2080-91	4.3 213
200	Pigmented epithelioid melanocytoma: a recently described melanocytic tumour of low malignant potential. <i>Pathology</i> , 2010 , 42, 284-6	1.6 13
199	Cutaneous Metastases 2010 , 637-650	2

198	Targeted Therapy Database (TTD): a model to match patient's molecular profile with current knowledge on cancer biology. <i>PLoS ONE</i> , 2010 , 5, e11965	3.7	11
197	Synchronous and metachronous malignancies in patients with melanoma: a clinicopathologic study highlighting the role of fine-needle biopsy cytology and potential diagnostic pitfalls. <i>Melanoma Research</i> , 2010 , 20, 203-11	3.3	6
196	Tumor-infiltrating lymphocytes and mitotic index in metastatic melanoma as predictors of patient survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, E46; author reply E47	11.5	2
195	Retroperitoneal inflammatory liposarcoma in a patient with non-hodgkin lymphoma: a report highlighting diagnostic pitfalls. <i>Pathology Research International</i> , 2010 , 2010, 505436		2
194	Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4441-9	2.2	93
193	Lymphoma occurring in patients with cutaneous melanoma. <i>Journal of Clinical Pathology</i> , 2010 , 63, 777-819		10
192	Morphologic features of melanophages under in vivo reflectance confocal microscopy. <i>Archives of Dermatology</i> , 2010 , 146, 492-8		32
191	Melanotic schwannoma mimicking metastatic pigmented melanoma: a pitfall in cytological diagnosis. <i>Pathology</i> , 2010 , 42, 287-9	1.6	12
190	Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. <i>Modern Pathology</i> , 2010 , 23, 45-53	9.8	56
189	IGFBP7 is not required for B-RAF-induced melanocyte senescence. <i>Cell</i> , 2010 , 141, 717-27	56.2	55
188	High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2010 , 23, 137-40	4.5	16
187	Genetic and morphologic features for melanoma classification. <i>Pigment Cell and Melanoma Research</i> , 2010 , 23, 763-70	4.5	116
186	Fine-needle biopsy of metastatic melanoma: clinical use and new applications. <i>Lancet Oncology</i> , 2010 , 11, 391-400	21.7	17
185	State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop. <i>Advances in Anatomic Pathology</i> , 2010 , 17, 73-90	5.1	72
184	Location of melanoma metastases in sentinel lymph nodes: what are the implications for histologic processing of sentinel lymph nodes in routine practice?. <i>American Journal of Surgical Pathology</i> , 2010 , 34, 127-9; author reply 129-31	6.7	4
183	Can histologic parameters of melanoma metastases in sentinel lymph nodes reliably select patients who can be safely spared completion lymph node dissection?. <i>Annals of Surgery</i> , 2010 , 251, 1188-9; author reply 1189-90	7.8	
182	Diagnostic value of 8.5 T magnetic resonance spectroscopy of benign and malignant skin lesion biopsies. <i>Melanoma Research</i> , 2010 , 20, 311-7	3.3	7
181	Sentinel lymph node biopsy in pediatric and adolescent cutaneous melanoma patients. <i>Annals of Surgical Oncology</i> , 2010 , 17, 138-43	3.1	56

180	The prognostic value of tumor mitotic rate and other clinicopathologic factors in patients with locoregional recurrences of melanoma. <i>Annals of Surgical Oncology</i> , 2010 , 17, 2992-9	3.1	7
179	Total sentinel lymph node tumor size predicts nonsentinel node metastasis and survival in patients with melanoma. <i>Annals of Surgical Oncology</i> , 2010 , 17, 3015-20	3.1	25
178	Sentinel node positive melanoma patients: prediction and prognostic significance of nonsentinel node metastases and development of a survival tree model. <i>Annals of Surgical Oncology</i> , 2010 , 17, 1995-2005	3.1	32
177	Atypical fibroxanthoma: differential diagnosis from other sarcomatoid skin lesions. <i>Diagnostic Histopathology</i> , 2010 , 16, 401-408	0.7	4
176	An extended antibody microarray for surface profiling metastatic melanoma. <i>Journal of Immunological Methods</i> , 2010 , 358, 23-34	2.5	21
175	Re-evaluation of a scoring system to predict nonsentinel-node metastasis and prognosis in melanoma patients. <i>Journal of the American College of Surgeons</i> , 2010 , 211, 522-5	4.4	11
174	Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients. <i>Cancer</i> , 2010 , 116, 4130-8	6.4	87
173	Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 8548-8548	2.2	4
172	Pitfalls and important issues in the pathologic diagnosis of melanocytic tumors. <i>Ochsner Journal</i> , 2010 , 10, 66-74	1.5	16
171	Histologically ambiguous ("borderline") primary cutaneous melanocytic tumors: approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy. <i>Archives of Pathology and Laboratory Medicine</i> , 2010 , 134, 1770-7	5	40
170	LC/MS-based quantitative proteomic analysis of paraffin-embedded archival melanomas reveals potential proteomic biomarkers associated with metastasis. <i>PLoS ONE</i> , 2009 , 4, e4430	3.7	52
169	Cutaneous metastasis of epithelioid haemangioendothelioma. <i>Pathology</i> , 2009 , 41, 585-7	1.6	4
168	Targeted high-resolution ultrasound is not an effective substitute for sentinel lymph node biopsy in patients with primary cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5614-9	2.2	80
167	Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours. <i>Journal of Clinical Pathology</i> , 2009 , 62, 1016-20	3.9	28
166	Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors. <i>International Journal of Surgical Pathology</i> , 2009 , 17, 361-7	1.2	38
165	Cytological features of melanoma in exfoliative fluid specimens. <i>Journal of Clinical Pathology</i> , 2009 , 62, 638-43	3.9	7
164	Primary cutaneous Ewing sarcoma/primitive neuroectodermal tumour: a clinicopathological analysis of seven cases highlighting diagnostic pitfalls and the role of FISH testing in diagnosis. <i>Journal of Clinical Pathology</i> , 2009 , 62, 915-9	3.9	30
163	Phyllodes tumours of the breast: a clinicopathological analysis of 65 cases from a single institution. <i>Breast</i> , 2009 , 18, 165-70	3.6	70

162	Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma. <i>Cancer</i> , 2009 , 115, 5026-37	6.4	68
161	So-called "malignant blue nevus": a clinicopathologic study of 23 patients. <i>Cancer</i> , 2009 , 115, 2949-55	6.4	54
160	Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors. <i>Breast Cancer Research and Treatment</i> , 2009 , 114, 441-8	4.4	44
159	EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009 , 36, 1713-42	8.8	140
158	Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma. <i>Histopathology</i> , 2009 , 54, 462-70	7.3	81
157	Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. <i>Journal of Investigative Dermatology</i> , 2009 , 129, 1972-82	4.3	23
156	Functional RET G691S polymorphism in cutaneous malignant melanoma. <i>Oncogene</i> , 2009 , 28, 3058-68	9.2	56
155	Surgical strategies and histopathologic issues in the management of lentigo maligna. <i>Annals of Surgical Oncology</i> , 2009 , 16, 1456-8	3.1	7
154	Surgery for melanoma metastases of the gastrointestinal tract: indications and results. <i>European Journal of Surgical Oncology</i> , 2009 , 35, 313-9	3.6	68
153	The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a. <i>Molecular Cancer</i> , 2009 , 8, 4	42.1	46
152	Elemental bio-imaging of melanoma in lymph node biopsies. <i>Analyst, The</i> , 2009 , 134, 450-3	5	46
151	Radiation recall dermatitis after pre-sensitization with pegylated liposomal doxorubicin. <i>Cancer Investigation</i> , 2009 , 27, 397-401	2.1	6
150	Cutaneous melanoma in the era of molecular profiling. <i>Lancet, The</i> , 2009 , 374, 362-5	40	83
149	Pigmented epithelioid melanocytoma: favorable outcome after 5-year follow-up. <i>American Journal of Surgical Pathology</i> , 2009 , 33, 1778-82	6.7	90
148	Interobserver variation in the histopathologic reporting of key prognostic parameters, particularly clark level, affects pathologic staging of primary cutaneous melanoma. <i>Annals of Surgery</i> , 2009 , 249, 641-7	7.8	36
147	Proposed quality standards for regional lymph node dissections in patients with melanoma. <i>Annals of Surgery</i> , 2009 , 249, 473-80	7.8	50
146	Sentinel node status prediction by four statistical models: results from a large bi-institutional series (n = 1132). <i>Annals of Surgery</i> , 2009 , 250, 964-9	7.8	21
145	Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas. <i>American Journal of Surgical Pathology</i> , 2009 , 33, 1386-95	6.7	85

144	False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy. <i>Melanoma Research</i> , 2009 , 19, 94-9	3.3	51
143	Blue nevi and related lesions: a review highlighting atypical and newly described variants, distinguishing features and diagnostic pitfalls. <i>Advances in Anatomic Pathology</i> , 2009 , 16, 365-82	5.1	116
142	Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. <i>Pathology</i> , 2009 , 41, 383-7	1.6	78
141	Pathogenic mechanisms in the initiation and progression of mammary phyllodes tumours. <i>Pathology</i> , 2009 , 41, 105-17	1.6	31
140	The role of intra-operative pathological evaluation in the management of musculoskeletal tumours. <i>Recent Results in Cancer Research</i> , 2009 , 179, 11-24	1.5	6
139	The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. <i>British Journal of Cancer</i> , 2008 , 98, 1085-93	8.7	47
138	Epidermolysis bullosa acquisita requiring multiple oesophageal dilatations. <i>Clinical and Experimental Dermatology</i> , 2008 , 33, 787-9	1.8	11
137	Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. <i>Histopathology</i> , 2008 , 53, 345	7.3	5
136	The detection and significance of melanoma micrometastases in sentinel nodes. <i>Surgical Oncology</i> , 2008 , 17, 165-74	2.5	39
135	Pathologic examination of sentinel lymph nodes from melanoma patients. <i>Seminars in Diagnostic Pathology</i> , 2008 , 25, 100-11	4.3	92
134	Fine-needle biopsy as a diagnostic technique for metastatic melanoma. <i>Expert Opinion on Medical Diagnostics</i> , 2008 , 2, 1-10		3
133	Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. <i>Clinical Cancer Research</i> , 2008 , 14, 638-45	12.9	115
132	Cytologic features of metastatic and recurrent melanoma in patients with primary cutaneous desmoplastic melanoma. <i>American Journal of Clinical Pathology</i> , 2008 , 130, 715-23	1.9	20
131	Sentinel lymph node biopsy for melanoma: aspects of pathologic assessment. <i>Future Oncology</i> , 2008 , 4, 535-51	3.6	18
130	Tumoural calcium pyrophosphate dihydrate crystal deposition disease (tophaceous pseudogout) of the hand: a report of two cases including one with a previously unreported associated florid reactive myofibroblastic proliferation. <i>Pathology</i> , 2008 , 40, 719-22	1.6	7
129	Angiotropism is an independent predictor of local recurrence and in-transit metastasis in primary cutaneous melanoma. <i>American Journal of Surgical Pathology</i> , 2008 , 32, 1396-403	6.7	61
128	False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology. <i>Annals of Surgery</i> , 2008 , 247, 1003-10	7.8	57
127	The prognostic significance of isolated immunohistochemically positive cells in sentinel lymph nodes of melanoma patients. <i>American Journal of Surgical Pathology</i> , 2008 , 32, 1106-7; author reply 1107-8	6.7	10

126	Correct identification of a sentinel node postselective lymphadenectomy using antimony levels. <i>Melanoma Research</i> , 2008 , 18, 365-6	3.3	
125	Merkel cell carcinoma with fibrosarcomatous differentiation. <i>Pathology</i> , 2008 , 40, 314-6	1.6	19
124	Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. <i>Histopathology</i> , 2008 , 52, 242; author reply 242-4	7.3	3
123	The advantage of using a synoptic pathology report format for cutaneous melanoma. <i>Histopathology</i> , 2008 , 52, 130-8	7.3	70
122	Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. <i>Cancer</i> , 2008 , 113, 2770-8	6.4	108
121	Diagnostic accuracy of fine needle biopsy for metastatic melanoma and its implications for patient management. <i>Annals of Surgical Oncology</i> , 2008 , 15, 323-32	3.1	25
120	Sentinel lymph node biopsy in histologically ambiguous melanocytic tumors with spitzoid features (so-called atypical spitzoid tumors). <i>Annals of Surgical Oncology</i> , 2008 , 15, 302-9	3.1	101
119	The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: analysis of 2303 melanoma patients treated at a single center. <i>Annals of Surgical Oncology</i> , 2008 , 15, 630-7	3.1	43
118	Confirmation of sentinel lymph node identity by analysis of fine-needle biopsy samples using inductively coupled plasma-mass spectrometry. <i>Annals of Surgical Oncology</i> , 2008 , 15, 934-40	3.1	4
117	Isolated limb infusion for advanced soft tissue sarcoma of the extremity. <i>Annals of Surgical Oncology</i> , 2008 , 15, 2749-56	3.1	44
116	Management of merkel cell carcinoma: the roles of lymphoscintigraphy, sentinel lymph node biopsy and adjuvant radiotherapy. <i>Annals of Surgical Oncology</i> , 2008 , 15, 2509-18	3.1	79
115	Re: NM patients and SN. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2007 , 5, 320	2.5	
114	Paratesticular rhabdomyoma. <i>Pathology</i> , 2007 , 39, 367-9	1.6	5
113	Primary Melanoma of the Lung. <i>American Surgeon</i> , 2007 , 73, 937-938	0.8	2
112	Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. <i>Modern Pathology</i> , 2007 , 20, 416-26	9.8	151
111	Merkel cell carcinoma: assessing the effect of wide local excision, lymph node dissection, and radiotherapy on recurrence and survival in early-stage disease—results from a review of 82 consecutive cases diagnosed between 1992 and 2004. <i>Annals of Surgical Oncology</i> , 2007 , 14, 1943-52	3.1	80
110	Epithelioid and spindle cell haemangioma of bone. <i>Skeletal Radiology</i> , 2007 , 36 Suppl 1, S50-7	2.7	10
109	Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours. <i>Journal of Clinical Pathology</i> , 2007 , 60, 1051-6	3.9	10

108	Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. <i>Annals of Oncology</i> , 2007 , 18, 806-8	10.3	14
107	Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. <i>Clinical Cancer Research</i> , 2007 , 13, 3825-30	12.9	59
106	Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries. <i>Journal of Clinical Pathology</i> , 2007 , 60, 622-6	3.9	16
105	Diagnosis of metastatic melanoma by fine-needle biopsy: analysis of 2,204 cases. <i>American Journal of Clinical Pathology</i> , 2007 , 127, 385-97	1.9	60
104	New evidence for geographic variation in the role of human papillomavirus in tonsillar carcinogenesis. <i>Pathology</i> , 2007 , 39, 217-22	1.6	33
103	Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. <i>Pathology</i> , 2007 , 39, 551-7	1.6	38
102	Subungual melanoma: a study of 124 cases highlighting features of early lesions, potential pitfalls in diagnosis, and guidelines for histologic reporting. <i>American Journal of Surgical Pathology</i> , 2007 , 31, 1902-12	6.7	132
101	Melanocytic nevus with focal atypical epithelioid components (clonal nevus) is a combined nevus. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, 889-90	4.5	14
100	An unusual variant of intraneural ganglion of the common peroneal nerve. <i>Skeletal Radiology</i> , 2006 , 35, 165-71	2.7	19
99	Myxoid variant of adrenocortical carcinoma: report of a unique case. <i>Pathology International</i> , 2006 , 56, 89-94	1.8	24
98	The role of cell cycle regulatory proteins in the pathogenesis of melanoma. <i>Pathology</i> , 2006 , 38, 287-301	1.6	100
97	Survival in patients with desmoplastic melanoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, e12; author reply e13	2.2	19
96	Surgical biopsy with intra-operative frozen section. An accurate and cost-effective method for diagnosis of musculoskeletal sarcomas. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2006 , 88, 1207-11		47
95	A distinct molecular profile associated with mucinous epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2006 , 94, 904-13	8.7	87
94	Myopericytoma: a unifying term for a spectrum of tumours that show overlapping features with myofibroma. A review of 14 cases. <i>Journal of Clinical Pathology</i> , 2006 , 59, 67-73	3.9	115
93	Surgical management of primary cutaneous melanoma: excision margins and the role of sentinel lymph node examination. <i>Surgical Oncology Clinics of North America</i> , 2006 , 15, 301-18	2.7	20
92	Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. <i>Human Pathology</i> , 2006 , 37, 1286-94	3.7	66
91	Primary Melanoma of the Lung 2006 , 293-297		7

90	The importance of mitotic rate as a prognostic factor for localized primary cutaneous melanoma. <i>Journal of Cutaneous Pathology</i> , 2006 , 33, 395-6; author reply 397-9	1.7	18
89	Pravastatin-induced lichenoid drug eruption. <i>Australasian Journal of Dermatology</i> , 2006 , 47, 57-9	1.3	34
88	Incomplete biopsy of melanocytic lesions can impair the accuracy of pathological diagnosis. <i>Australasian Journal of Dermatology</i> , 2006 , 47, 71-3; author reply 74-5	1.3	22
87	Cutaneous melanoma. <i>Lancet, The</i> , 2005 , 365, 687-701	4.0	463
86	Cutaneous melanoma. <i>Lancet, The</i> , 2005 , 365, 2003; author reply 2004-5	4.0	3
85	Cutaneous melanoma. <i>Lancet, The</i> , 2005 , 365, 2004-2005	4.0	2
84	In vivo and ex vivo proton MR spectroscopy of primary and secondary melanoma. <i>European Journal of Radiology</i> , 2005 , 53, 506-13	4.7	22
83	Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. <i>Annals of Surgical Oncology</i> , 2005 , 12, 429-39	3.1	102
82	Condylomata acuminata of the urinary bladder with HPV 11. <i>Pathology</i> , 2005 , 37, 176-8	1.6	8
81	Histopathologic excision margin affects local recurrence rate: analysis of 2681 patients with melanomas <i>Annals of Surgery</i> , 2005 , 241, 326-33	7.8	45
80	Isolated melanoma in the lung where there is no known primary site: metastatic disease or primary lung tumour?. <i>Melanoma Research</i> , 2005 , 15, 531-7	3.3	36
79	Melanoma metastases in regional lymph nodes are accurately detected by proton magnetic resonance spectroscopy of fine-needle aspirate biopsy samples. <i>Annals of Surgical Oncology</i> , 2005 , 12, 943-9	3.1	18
78	A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. <i>Annals of Surgical Oncology</i> , 2005 , 12, 597-608	3.1	59
77	Borderline lepromatous leprosy presenting as a single cutaneous plaque. <i>Australasian Journal of Dermatology</i> , 2005 , 46, 181-3	1.3	9
76	Eccrine porocarcinoma of the upper eyelid. <i>Australasian Journal of Dermatology</i> , 2005 , 46, 278-81	1.3	27
75	Intraoperative frozen-section evaluation can reduce accuracy of pathologic assessment of sentinel nodes in melanoma patients. <i>Journal of the American College of Surgeons</i> , 2005 , 201, 821-3; author reply 823-4	4.4	28
74	Transforming growth factor-beta1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 898-906	7.4	56
73	Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cutaneous melanoma. <i>Annals of Surgical Oncology</i> , 2005 , 12, 18-23	3.1	89

72	Selective sentinel lymphadenectomy: progress to date and prospects for the future. <i>Cancer Treatment and Research</i> , 2005 , 127, 269-87	3.5	12
71	Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. <i>Journal of Clinical Pathology</i> , 2005 , 58, 185-9	3.9	45
70	Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour. <i>Journal of Clinical Pathology</i> , 2005 , 58, 600-4	3.9	23
69	Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. <i>Journal of Clinical Pathology</i> , 2005 , 58, 1163-9	3.9	70
68	Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 4427-36	12.9	169
67	Desmoplastic melanoma: a diagnostic trap for the unwary. <i>Pathology</i> , 2004 , 36, 445-51	1.6	70
66	Polymorphous low-grade adenocarcinoma in the lung: a case report. <i>International Journal of Surgical Pathology</i> , 2004 , 12, 287-92	1.2	15
65	Myoid angioendothelioma of the spleen. <i>International Journal of Surgical Pathology</i> , 2004 , 12, 51-6	1.2	13
64	Micromorphometric Features of Positive Sentinel Lymph Nodes Predict Involvement of Nonsentinel Nodes in Patients With Melanoma. <i>American Journal of Clinical Pathology</i> , 2004 , 122, 532-539	1.9	107
63	Unusual case of subcutaneous panniculitis-like T-cell lymphoma. <i>Australasian Journal of Dermatology</i> , 2004 , 45, 114-8	1.3	9
62	Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. <i>Modern Pathology</i> , 2004 , 17, 827-31	9.8	60
61	The site of infection and ethnicity of the patient influence the biological pathways to HPV-induced mucosal cancer. <i>Modern Pathology</i> , 2004 , 17, 1031-7	9.8	8
60	Antimony concentrations in nodal tissue can confirm sentinel node identity. <i>Modern Pathology</i> , 2004 , 17, 1191-7	9.8	15
59	Parachordoma is not distinguishable from axial chordoma using immunohistochemistry. <i>Pathology International</i> , 2004 , 54, 364-70	1.8	17
58	Progressive visual loss in a patient with presumed temporal arteritis despite treatment: how to make the diagnosis. <i>Clinical and Experimental Ophthalmology</i> , 2004 , 32, 335-6	2.4	6
57	Sentinel node biopsy for melanoma: Where have we been and where are we going?. <i>Annals of Surgical Oncology</i> , 2004 , 11, 147S-51S	3.1	13
56	Failure to remove true sentinel nodes can cause failure of the sentinel node biopsy technique: evidence from antimony concentrations in false-negative sentinel nodes from melanoma patients. <i>Annals of Surgical Oncology</i> , 2004 , 11, 174S-8S	3.1	10
55	Epiphyseal osteoblastoma-like osteosarcoma. <i>Skeletal Radiology</i> , 2004 , 33, 46-50	2.7	12

54	The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil. <i>Head and Neck</i> , 2004 , 26, 1-9	4.2	91
53	Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision. <i>Cancer</i> , 2004 , 101, 2141-2; author reply 2142-3	6.4	17
52	The history and future of melanoma staging. <i>Journal of Surgical Oncology</i> , 2004 , 86, 224-35	2.8	17
51	Pathology of melanocytic lesions: new, controversial, and clinically important issues. <i>Journal of Surgical Oncology</i> , 2004 , 86, 200-11	2.8	42
50	Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma. <i>Annals of Surgical Oncology</i> , 2004 , 11, 829-36	3.1	60
49	The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. <i>Annals of Surgical Oncology</i> , 2004 , 11, 426-33	3.1	163
48	The significance of the Wnt pathway in the pathology of human cancers. <i>Pathology</i> , 2004 , 36, 120-8	1.6	218
47	Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases. <i>Human Pathology</i> , 2004 , 35, 1053-7	3.7	59
46	Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. <i>Pathology</i> , 2004 , 36, 561-5	1.6	15
45	Correlation between preoperative lymphoscintigraphy and metastatic nodal disease sites in 362 patients with cutaneous melanomas of the head and neck. <i>Annals of Surgery</i> , 2004 , 239, 544-52	7.8	91
44	Immunohistochemical stains fail to increase the detection rate of micrometastatic melanoma in completion regional lymph node dissection specimens. <i>Melanoma Research</i> , 2004 , 14, 263-8	3.3	17
43	Pigmented epithelioid melanocytoma. <i>American Journal of Surgical Pathology</i> , 2004 , 28, 1114-5; author reply 1115-6	6.7	35
42	Combined naevus: a benign lesion frequently misdiagnosed both clinically and pathologically as melanoma. <i>Pathology</i> , 2004 , 36, 419-27	1.6	49
41	Spitz naevus: diagnostic problems and their management implications. <i>Pathology</i> , 2004 , 36, 452-7	1.6	41
40	Cooperation between surgical oncologists and pathologists: a key element of multidisciplinary care for patients with cancer. <i>Pathology</i> , 2004 , 36, 496-503	1.6	31
39	Failure to Remove True Sentinel Nodes Can Cause Failure of the Sentinel Node Biopsy Technique: Evidence from Antimony Concentrations in False-Negative Sentinel Nodes from Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2004 , 11, 174S-178S	3.1	27
38	Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. <i>American Journal of Clinical Pathology</i> , 2004 , 122, 532-9	1.9	23
37	Alcoholism and dementia 2004 , 427-441		2

36	Melanocytic lesions of the face: diagnostic pitfalls. <i>Annals of the Academy of Medicine, Singapore</i> , 2004 , 33, 3-14	2.8	9
35	Clinical case seminar: Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 4088-94	5.6	83
34	Increased expression of apoptotic markers in melanoma. <i>Melanoma Research</i> , 2003 , 13, 137-45	3.3	44
33	Use of multiple cytometric markers improves discrimination between benign and malignant melanocytic lesions: a study of DNA microdensitometry, karyometry, argyrophilic staining of nucleolar organizer regions and MIB1-Ki67 immunoreactivity. <i>Melanoma Research</i> , 2003 , 13, 581-6	3.3	15
32	Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. <i>American Journal of Surgical Pathology</i> , 2003 , 27, 1571-6	6.7	129
31	Rapid detection of metastatic melanoma in lymph nodes using proton magnetic resonance spectroscopy of fine needle aspiration biopsy specimens. <i>Melanoma Research</i> , 2003 , 13, 259-61	3.3	24
30	Argyrophilic staining of nucleolar organizer region count and morphometry in benign and malignant melanocytic lesions. <i>American Journal of Dermatopathology</i> , 2003 , 25, 190-7	0.9	24
29	Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence: a clinicopathologic study of 1152 patients undergoing sentinel lymph node biopsy. <i>American Journal of Surgical Pathology</i> , 2003 , 27, 1197-202	6.7	89
28	Intramuscular dendritic fibromyxolipoma: myxoid variant of spindle cell lipoma?. <i>Pathology International</i> , 2003 , 53, 252-8	1.8	24
27	Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. <i>Cancer</i> , 2003 , 97, 1488-98	6.4	315
26	Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. <i>International Journal of Cancer</i> , 2003 , 106, 553-558	7.5	182
25	Tumour angiogenesis and p53 protein expression in mammary phyllodes tumors. <i>Modern Pathology</i> , 2003 , 16, 1007-13	9.8	33
24	Absence of human papillomavirus in tonsillar squamous cell carcinomas from Chinese patients. <i>American Journal of Pathology</i> , 2003 , 163, 2185-9	5.8	32
23	Antimony by ICP-MS as a marker for sentinel lymph nodes in melanoma patients. <i>Analyst, The</i> , 2003 , 128, 217-9	5	15
22	Challenging and unusual cases: Case 4. Malignant mesothelioma presenting as an anterior mediastinal mass. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1420-1	2.2	
21	Aggressive endometriosis. <i>International Journal of Gynecological Cancer</i> , 2003 , 13, 98-99; author reply 100	3.5	3
20	Test and teach. Diagnosis: Subcutaneous Rosai-Dorfman disease. <i>Pathology</i> , 2002 , 34, 466-70	1.6	
19	Clinical and histologic features of level 2 cutaneous malignant melanoma associated with metastasis. <i>Cancer</i> , 2002 , 95, 671-2; author reply 672-3	6.4	

18	Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases. <i>American Journal of Clinical Pathology</i> , 2002 , 118, 522-6	1.9	58
17	Increased p53 protein expression in malignant mammary phyllodes tumors. <i>Modern Pathology</i> , 2002 , 15, 734-40	9.8	59
16	Spitz naevus versus Spitzoid melanoma: when and how can they be distinguished?. <i>Pathology</i> , 2002 , 34, 6-12	1.6	90
15	An unusual pleural spindle cell tumour. Part 1. <i>Pathology</i> , 2002 , 34, 370-4	1.6	3
14	Pagetoid spread of melanocytes in Spitz naevi: authors' reply. <i>Pathology</i> , 2002 , 34, 591	1.6	5
13	Hyalinising spindle cell tumour with giant rosettes: report of a case with unusual features including original histological and ultrastructural observations. <i>Pathology</i> , 2001 , 33, 101-7	1.6	5
12	Can phyllodes tumours of the breast be distinguished from fibroadenomas using fine needle aspiration cytology?. <i>Pathology</i> , 2001 , 33, 437-43	1.6	29
11	Spinal chloroma presenting with triplegia in an aleukaemic patient. <i>Pathology</i> , 2001 , 33, 386-389	1.6	16
10	SPINAL CHLOROMA PRESENTING WITH TRIPLEGIA IN AN ALEUKAEMIC PATIENT. <i>Pathology</i> , 2001 , 33, 386-389	1.6	3
9	Acute basophilic leukemia presenting with abnormal liver function tests and the absence of blast cells in the peripheral blood. <i>Pathology</i> , 2000 , 32, 52-5	1.6	5
8	Aggressive endometriosis: report of a case. <i>International Journal of Gynecological Cancer</i> , 2000 , 10, 257-262	1.6	11
7	Middle lobe syndrome due to obstructing solitary bronchial papilloma. <i>Australian and New Zealand Journal of Medicine</i> , 1999 , 29, 745-7		5
6	Hepatocellular carcinoma metastasizing to the orbit diagnosed by fine needle aspiration cytology. <i>Pathology</i> , 1999 , 31, 350-3	1.6	11
5	Test and teach. Number ninety six: Part 1. Inverted duct papilloma of minor salivary gland origin. <i>Pathology</i> , 1999 , 31, 372, 423-4	1.6	1
4	Test and teach. Number ninety-four: Part 1. Churg-Strauss syndrome. <i>Pathology</i> , 1999 , 31, 217-8, 275-7	1.6	2
3	Hotspot KRAS mutations in brain metastases at the first metastatic recurrence of cutaneous melanoma		1
2	Anatomic position determines oncogenic specificity in melanoma		2
1	Sentinel lymph node biopsy rates in Victoria, 2018 and 2019. <i>Medical Journal of Australia</i> ,	4	

